Yuki Noguchi
speaker
599 appearances
112 recordings
1 series
first heard Feb 2025
last heard 3d ago
Yuki Noguchi’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 86 in all, peaking in Jul 2026 with 19.
Appearances
In some studies, using these technologies close to doubled the length of survival for patients.
Researchers say breakthroughs like these are increasingly enabling medical treatment that is personalized to patients.
Yukina Gucci, NPR News.
AI is increasingly used in a variety of ways to identify, track, and personalize the treatment of cancers.
Several new research studies unveiled at the European Society for Medical Oncology this week show how the technology can better detect cancers in things like CT scans of mesothelioma or track recurrent disease using blood-based biomarkers in colorectal or lung cancers.
In some studies, using these technologies close to doubled the length of survival for patients.
Yukina Gucci, NPR News.
AI is increasingly used in a variety of ways to identify, track, and personalize the treatment of cancers.
In some studies, using these technologies close to doubled the length of survival for patients.
Yukina Gucci, NPR News.
President Trump warned pregnant women last month against taking acetaminophen, the ingredient in Tylenol, claiming it causes autism.
Doctors say there's no causal evidence for that and say taking Tylenol is safer than a fever in pregnancy.
So what's the public reaction?
The poll by KFF found nearly 60 percent of Democrats say the president's statements were definitely false, but an almost equal percentage of Republicans believe the opposite.
Ashley Kersinger directed the poll for KFF, a health policy research organization.
The study looked at what happened when a drug called niraparib, which treats ovarian and breast cancer, is added to a combination of two other drugs used as standard treatment for prostate cancer.
Researchers at the University College of London followed 700 patients with certain genetic alterations in their prostate cancer for over two and a half years.
It found adding the third drug reduced risk of progression by 37 percent overall and nearly half among those with certain specific genetic markers.
The combination also significantly delayed onset of symptoms.
The study looked at what happened when a drug called niraparib, which treats ovarian and breast cancer, is added to a combination of two other drugs used as standard treatment for prostate cancer.
Showing 441–460 of 599 · page 23 of 30
← Previous
Next →